Prospect: information for the patient
Topiramato Qualigen 25 mg film-coated tablets EFG
This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this prospectus carefully before starting to take this medicine, as it contains important information for you.
1. What is Topiramato Qualigen and for what it is used
2. What you need to know before starting to take Topiramato Qualigen
3. How to take Topiramato Qualigen
4. Possible adverse effects
5. Storage of Topiramato Qualigen
6. Contents of the package and additional information
Topiramato Qualigen belongs to a group of medications called «antiepileptics». It is used:
Do not take Topiramato Qualigen
Prevention of migraines
Treatment of epilepsy
Make sure you read the patient leaflet that your doctor will give you or scan the QR code to obtain it (see section 6 “Other sources of information”)
A patient card is provided with the packaging of Topiramato Qualigen to remind you of the risks during pregnancy.
If you are unsure whether the above applies to your case, consult your doctor or pharmacist before taking Topiramato Qualigen.
Warnings and precautions
Consult your doctor before starting to take Topiramato Qualigen if you:
If you are unsure whether the above applies to your case, consult your doctor before usingTopiramato Qualigen.
If you have epilepsy, it is essential not to stop taking your medication without consulting your doctor first.
You should also consult your doctor before taking any medication that contains topiramate that may be given to you as an alternative to Topiramato Qualigen.
A small number of people being treated with antiepileptic drugs such as Topiramato Qualigen have had thoughts of harming themselves or taking their own lives. If you ever have these thoughts, contact your doctor immediately.
If you are taking Topiramato Qualigen, you may lose weight, so you should weigh yourself regularly while taking this medicine. If you are losing too much weight, consult your doctor.
In rare cases, Topiramato Qualigen may cause high levels of ammonia in the blood (seen in blood tests), which can cause a change in brain function, especially if you are also taking a medicine called valproic acid or sodium valproate. Since this may be a serious condition, inform your doctor immediately if you experience the following symptoms (see also section 4 “Possible side effects”):
• difficulty thinking, remembering information, or solving problems
• being less alert or conscious
• feeling very sleepy and having little energy
With higher doses of Topiramato Qualigen, the risk of developing these symptoms may increase.
Children and adolescents
If a child taking this medicine is not at a healthy weight, they should be consulted with a doctor.
Other medicines and Topiramato Qualigen
Inform your doctor or pharmacist if you are using, have used recently, or should use other medicines. The effect of Topiramato Qualigen and other medicines may be altered if taken together.
In some cases, it may be necessary to adjust the dose of the other medicines or Topiramato Qualigen.
Especially, inform your doctor or pharmacist if you are taking:
Inform your doctor if you change your menstrual bleeding while taking hormonal contraceptives and Topiramato Qualigen. You may experience irregular bleeding. In this case, continue taking the hormonal contraceptives and inform your doctor.
Make a list of all the medicines you take. Show the list to your doctor or pharmacist before starting to take this medicine.
Among the medicines you need to inform your doctor or pharmacist about are other antiepileptic medicines, risperidone, lithium, hydrochlorothiazide, metformin, pioglitazone, glibenclamide, amitriptyline, propranolol, diltiazem, venlafaxine, flunarizine, St. John's Wort (Hypericum perforatum) (a herbal preparation used to treat depression),warfarin used to prevent blood clotting.
If you are unsure whether the above applies to your case, consult your doctor or pharmacist before taking Topiramato Qualigen.
Topiramato Qualigen with food, drinks, and alcohol
You can take Topiramato Qualigen with or without food. While taking Topiramato Qualigen, it is recommended to drink plenty of fluids during the day to prevent kidney stones. While taking Topiramato Qualigen, you should avoid drinking alcohol.
Pregnancy, breastfeeding, and fertility
Pregnancy
Important advice for fertile women:
Topiramato Qualigen may cause harm to a baby during pregnancy. If you are a fertile woman, consult your doctor about other possible treatments. Visit your doctor to review your treatment and discuss the risks at least once a year.
Prevention of migraines
Treatment of epilepsy:
Risks of topiramate when taken during pregnancy (regardless of the condition for which topiramate is used) are as follows:
There is a risk of harm to the baby during pregnancy if Topiramato Qualigen is used during pregnancy.
Need for contraceptive methods for fertile women:
Use of Topiramato Qualigen in girls:
If you are the parent/caregiver of a girl treated with Topiramato Qualigen, you should consult your doctor immediately once your daughter experiences her first menstrual period (menarche). The doctor will inform you about the risks to a baby during pregnancy due to exposure to topiramate during pregnancy and about the need to use highly effective contraceptive methods.
If you want to become pregnant while taking Topiramato Qualigen:
If you have become pregnant or think you may be pregnant while taking Topiramato Qualigen:
Make sure you read the patient leaflet that your doctor will give you. The patient leaflet is also available by scanning a QR code; see section 6 “Other sources of information”
A patient card is provided with the packaging of Topiramato Qualigen to remind you of the risks during pregnancy.
Breastfeeding
The active ingredient of Topiramato Qualigen (topiramate) passes into breast milk. Effects have been observed in breastfed babies of mothers treated with Topiramato Qualigen, including diarrhea, feeling sleepy, feeling irritable, and low weight gain. Therefore, your doctor will discuss with you whether to interrupt breastfeeding or whether to interrupt the treatment with Topiramato Qualigen. Your doctor will take into account the importance of the benefits for the mother and the risk to the baby.
Mothers in the breastfeeding period who are taking Topiramato Qualigen should inform their doctor as soon as possible if the baby experiences anything unusual.
Driving and operating machines
During treatment with Topiramato Qualigen, you may experience dizziness, fatigue, and visual problems. Do not drive a vehicle or operate tools or machines without consulting your doctor first.
Topiramato Qualigen 25 mg contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Follow exactly the administration instructions for this medication as indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.
Girls and fertile women:
Topiramato Qualigen treatment should begin and continue under the supervision of a doctor experienced in treating epilepsy or migraine. Visit your doctor to review your treatment at least once a year.
If you take more Topiramato Qualigen than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
Taking other medications with Topiramato Qualigen may cause an overdose.
If you forget to take Topiramato Qualigen
If you interrupt treatment with Topiramato Qualigen
Do not stop taking this medication unless your doctor tells you to. Symptoms may return. If your doctor decides to stop treatment, it is possible that they will gradually reduce the dose over several days.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
Consult your doctor or seek immediate medical attention if you experience the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from available data):
Other side effects include the following, if severe, please consult your doctor or pharmacist:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Unknown (cannot be estimated from available data)
Children and adolescents
Generally, side effects observed in children are similar to those observed in adults. However, some side effects appear more frequently in children and/or may be more severe in children than in adults. More severe side effects include decreased or absent sweating and increased blood acidity. Side effects that may appear more frequently in children include upper respiratory tract diseases.
If you experience side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this prospectus.
Reporting side effects
If you experience side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this prospectus. You can also report side effects through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date shown on the packaging. The expiration date is the last day of the month indicated.
Do not dispose of medications through drains or in the trash. Dispose of packaging and unused medications at the pharmacy's designated collection point. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Topiramato Qualigen 25 mg
- The active ingredient is topiramate.
- Each film-coated tablet of Topiramato Qualigen 25 mg contains 25 mg of topiramate.
-The other components are:
Core:Microcrystalline cellulose, mannitol, sodium starch glycolate, pregelatinized cornstarch L.M, crospovidone, povidone, magnesium stearate, carnauba wax.
Coating:Hydroxypropyl methylcellulose, lactose monohydrate, macrogol 4000, titanium dioxide (E 171).
Appearance of Topiramato Qualigen 25 mg and packaging contents
Topiramato Qualigen 25 mg film-coated tablets are round and white.
Packaging size: 60 tablets in HDPE containers containing a desiccant bag or in blisters.
Other sources of information
The most recent approved information, patient guide, on this medication is available by scanning the following QR code with a smartphone. The same information is also available on the following website (URL):
https://cima.aemps.es/cima/DocsPub/16/3252
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí – Barcelona
Spain
Responsible manufacturer
Pharmathen, S.A.
6, Dervenakion str.
153 51 Pallini, Attiki
Greece
Ó
G.L. PHARMA GMBH
Schlossplatz 1
Lannach
Austria
This medication is authorized in the EEA member states with the following names:
DK/H/1354/001-004/MR
Denmark:Maritop
Austria:Topiramat Gerot 25 mg/50 mg/100 mg/200 mg Filmtabletten
Bulgaria: Topilex25 mg/50 mg/100 mg
Czech Republic:Topilex 25 mg/50 mg/100 mg coated tablets
Romania:Topilex 25 mg/50 mg/100 mg/200 mg
Slovakia:Topilex 25 mg/50 mg/100 mg/200 mg
Spain:Topiramato Qualigen 25 mg/50 mg/100 mg/200 mg
This leaflet was revised in May 2024
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.